Slifka MK, Amanna IJ. Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses. Front. Immunol., 01 May 2019.

Quintel BK, Thomas A, Poer DeRaad DE, Slifka MK, Amanna IJ. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Vaccine. 2019 Jul 9;37(30):4214-4221. doi: 10.1016/j.vaccine.2018.12.020.

Woods CW, Sanchez AM, Swamy GK, McClain MT, Harrington L, Freeman D, Poore EA, Slifka DK, Poer DeRaad DE, Amanna IJ, Slifka MK, Cai S, Shahamatdar V, Wierzbicki MR, Amegashie C, Walter EB. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. Vaccine. 2019 Jul 9;37(30):4222-4230. doi: 10.1016/j.vaccine.2018.12.026.

Slifka MK, Amanna IJ. Dengue Serostatus and Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018 Nov 15;379(20):1968. doi: 10.1056/NEJMc1811986.

Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R, Slifka M. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 2018 Aug 10;16(8):e2006601. doi: 10.1371/journal.pbio.2006601.

Amanna IJ, Slifka MK. Successful Vaccines. Curr Top Microbiol Immunol. 2018 Jul 26. doi: 10.1007/82_2018_102.

Poore EA, Slifka DK, Raué HP, Thomas A, Hammarlund E, Quintel BK, Torrey LL, Slifka AM, Richner JM, Dubois ME, Johnson LP, Diamond MS, Slifka MK, Amanna IJ. Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine. 2017 Jan 5;35(2):283-292.

Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016 Dec;15(12):1519-1533.

Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, Chen Z, Slifka MK. Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis. Clin Infect Dis. 2016 May 1;62(9):1111-1118.

Slifka MK, Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine. 2014 May 23;32(25):2948-57.

Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert Rev Vaccines. 2014 May;13(5):589-608.

Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ. Antiviral Immune Response After Live Yellow Fever Vaccination of a Kidney Transplant Recipient Treated With IVIG. Transplantation. 2013 May 15;95(9)

Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, Diamond MS. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol. 2013 Feb;87(4):1926-36.

Amanna IJ, Hammarlund E, Lewis MW, Slifka MK. Impact of infection or vaccination on pre-existing serological memory. Hum Immunol. 2012 Nov;73(11):1082-6.

Amanna IJ. Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci. 2012 Jun 29;6(2012):64-72.

Amanna IJ, Raué HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012 Jun;18(6):974-9.

Dubois ME, Hammarlund E, Slifka MK. Optimization of peptide-based ELISA for serological diagnostics: a retrospective study of human monkeypox infection. Vector Borne Zoonotic Dis. 2012 May;12(5):400-9.

Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F, Messaoudi I, Slifka MK. A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus. PLoS One. 2012;7(9).

Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 2011 Mar 15;411(2):206-15.

Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res. 2009 Nov;84(2):119-30.